News
The cyclin-dependent kinase (CDK) inhibitor palbociclib, in combination with fulvestrant, increases progressionfree survival for women with hormone receptor (HR)-positive, HER2negative breast cancer compared with fulvestrant alone, according to results of the phase 3 PALOMA3 trial. In the study, 521 patients with HR-positive, HER2-negative breast cancer that had relapsed or progressed on previous endocrine therapy were randomly assigned to either palbociclib and the standard-ofcare drug fulvestrant or to placebo and fulvestrant. Women who were premenopausal or perimenopausal were also given goserelin. Patients who received the combined regimen had more than double the median progression-free survival (9·2 months [95% CI 7·5 to not estimable]) compared with those who received placebo (3·8 months
[3·5–5·5]; hazard ratio for disease progression or death 0·42 [95% CI 0·32–0·56]; p
The cyclin-dependent kinase (CDK) inhibitor palbociclib, in combination with fulvestrant, increases progressionfree survival for women with hormone receptor (HR)-positive, HER2negative breast cancer compared with fulvestrant alone, according to results of the phase 3 PALOMA3 trial. In the study, 521 patients with HR-positive, HER2-negative breast cancer that had relapsed or progressed on previous endocrine therapy were randomly assigned to either palbociclib and the standard-ofcare drug fulvestrant or to placebo and fulvestrant. Women who were premenopausal or perimenopausal were also given goserelin. Patients who received the combined regimen had more than double the median progression-free survival (9·2 months [95% CI 7·5 to not estimable]) compared with those who received placebo (3·8 months
[3·5–5·5]; hazard ratio for disease progression or death 0·42 [95% CI 0·32–0·56]; p
